Gendius Announces Funding From Catapult Ventures To Launch Innovative Digital Health Platform For Patients Living With Diabetes
Alderley Park, UK – 5th October 2017. Gendius, a digital health start-up developing a solution for patients living with diabetes to better manage their condition, today announced the completion of a Series A funding to launch Intellin® - an App based platform for people living with diabetes. The funding came from the GM&C Life Sciences Fund, managed by Catapult Ventures.
Diabetes is a global epidemic. The economic cost of treating diabetes in 2014 is estimated at over $600bn and the latest WHO report predicts there will be 592m sufferers around the world by 2035. Healthcare systems are desperate for novel solutions to engage and empower people to manage their diabetes more effectively and mobile technologies are spearheading many of these initiatives, and are predicted to be worth US$102.43bn by 2022, largely driven by Applications.
Gendius was founded by Chris Genders and Rory Cameron with a view to making living with diabetes easier. The company has developed Intellin® - an App platform that uses an individual’s clinical history to predict those areas most likely of developing complications from their diabetes i.e. their individual high-risk areas. The platform then focusses the individual on clinically validated tasks and measures to slow their progression in these areas. The Intellin® platform is currently undergoing clinical trials and has won significant grant funding from both Innovate UK and the SBRI.
In addition to the investment, Chris Spencer, a Digital Health Advisor with Catapult Ventures, will join the board of Gendius as non-executive Chairman in early 2018. Until April 2017 Chris was CEO of EMIS Group Plc where he had held senior roles since 1999.
Chris Genders, CEO Gendius, said “I’m extremely pleased to welcome the GM&C Life Sciences Fund as an investor in Gendius and welcome Chris as Chair elect. Chris’s wide-ranging experience in the leadership and management of healthcare technology businesses will be extremely valuable to Gendius as we seek to further enhance and commercialise our digital applications for diabetes and grow Gendius as a leader in this area.”
Dr Vijay Barathan, Life Science Partner with Catapult Ventures, said “We are excited by this opportunity and fully support the approach Gendius is taking to develop a scalable and sustainable digital health business.”
Chris Spencer, Digital Health Advisor with Catapult Ventures, said “I am looking forward to working with Chris, Rory, and the team to fulfil the potential of their Application to improve clinical outcomes in this area of high patient need and payer/provider cost.”
Contact:
Dr Vijay Barathan, Life Science Partner
E: vijay@catapult-ventures.com
T: 01625 344300 M: 07832 350820
Notes to Editors:
About GM&C Life Sciences Fund
Managed by Catapult Ventures, the GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region.
The Fund is the result of a collaboration between Cheshire and Warrington Local Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships and can be invested in ‘Life Science’ businesses across the following sectors:
• Pharmaceuticals
• Biotechnology
• Diagnostics
• Life Science contract research organisations (CRO)
• Healthcare technologies
• Medical devices
With contributions from both private and public-sector partners, the size of the Fund, at launch, is around £31m. Full details can be found at: www.gmclifesciencesfund.com
About Catapult Ventures
Catapult Ventures is an independent venture capital fund manager that has been investing in UK businesses across a range of sectors since 2002. Catapult’s owners operate a number of discrete funds on behalf of public and private sector investors with a total of c. £130m under the owners’ management. Notable realisations (over 4x return) include Blackstar Amps (4.3x), R5 Pharmaceuticals (4.7x), Whelan Refining (4.7x), QEK (4.5x), Lumora (5x), Oxford Cryosystems (5.2x), Systems Integration (4.9x) and Accutronics (9.1x). Catapult also invested in Abzena (AIM: ABZA) which listed in 2014.
About Gendius
Set up just over two years ago by Chris Genders and Rory Cameron our background is in Pharmaceuticals and Health Economics. We bring the disciplines of proving efficacy and value, through clinical trials and evidence, to the mobile health market. Our Intellin™ App based platform is designed with one thing in mind - helping people live better with diabetes.
Chris has taken his personal journey of living with diabetes and added this to his work with patient groups and healthcare professionals to develop a product that is individual and focusses on improving the development of future complications. Gendius in the last 12 months have won Innovate grant funding for a study in patients with Diabetic Foot Ulcers and in addition SBRI funding for a feasibility study in Gestational Diabetes.
www.gendius.co.uk
Diabetes is a global epidemic. The economic cost of treating diabetes in 2014 is estimated at over $600bn and the latest WHO report predicts there will be 592m sufferers around the world by 2035. Healthcare systems are desperate for novel solutions to engage and empower people to manage their diabetes more effectively and mobile technologies are spearheading many of these initiatives, and are predicted to be worth US$102.43bn by 2022, largely driven by Applications.
Gendius was founded by Chris Genders and Rory Cameron with a view to making living with diabetes easier. The company has developed Intellin® - an App platform that uses an individual’s clinical history to predict those areas most likely of developing complications from their diabetes i.e. their individual high-risk areas. The platform then focusses the individual on clinically validated tasks and measures to slow their progression in these areas. The Intellin® platform is currently undergoing clinical trials and has won significant grant funding from both Innovate UK and the SBRI.
In addition to the investment, Chris Spencer, a Digital Health Advisor with Catapult Ventures, will join the board of Gendius as non-executive Chairman in early 2018. Until April 2017 Chris was CEO of EMIS Group Plc where he had held senior roles since 1999.
Chris Genders, CEO Gendius, said “I’m extremely pleased to welcome the GM&C Life Sciences Fund as an investor in Gendius and welcome Chris as Chair elect. Chris’s wide-ranging experience in the leadership and management of healthcare technology businesses will be extremely valuable to Gendius as we seek to further enhance and commercialise our digital applications for diabetes and grow Gendius as a leader in this area.”
Dr Vijay Barathan, Life Science Partner with Catapult Ventures, said “We are excited by this opportunity and fully support the approach Gendius is taking to develop a scalable and sustainable digital health business.”
Chris Spencer, Digital Health Advisor with Catapult Ventures, said “I am looking forward to working with Chris, Rory, and the team to fulfil the potential of their Application to improve clinical outcomes in this area of high patient need and payer/provider cost.”
Contact:
Dr Vijay Barathan, Life Science Partner
E: vijay@catapult-ventures.com
T: 01625 344300 M: 07832 350820
Notes to Editors:
About GM&C Life Sciences Fund
Managed by Catapult Ventures, the GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region.
The Fund is the result of a collaboration between Cheshire and Warrington Local Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships and can be invested in ‘Life Science’ businesses across the following sectors:
• Pharmaceuticals
• Biotechnology
• Diagnostics
• Life Science contract research organisations (CRO)
• Healthcare technologies
• Medical devices
With contributions from both private and public-sector partners, the size of the Fund, at launch, is around £31m. Full details can be found at: www.gmclifesciencesfund.com
About Catapult Ventures
Catapult Ventures is an independent venture capital fund manager that has been investing in UK businesses across a range of sectors since 2002. Catapult’s owners operate a number of discrete funds on behalf of public and private sector investors with a total of c. £130m under the owners’ management. Notable realisations (over 4x return) include Blackstar Amps (4.3x), R5 Pharmaceuticals (4.7x), Whelan Refining (4.7x), QEK (4.5x), Lumora (5x), Oxford Cryosystems (5.2x), Systems Integration (4.9x) and Accutronics (9.1x). Catapult also invested in Abzena (AIM: ABZA) which listed in 2014.
About Gendius
Set up just over two years ago by Chris Genders and Rory Cameron our background is in Pharmaceuticals and Health Economics. We bring the disciplines of proving efficacy and value, through clinical trials and evidence, to the mobile health market. Our Intellin™ App based platform is designed with one thing in mind - helping people live better with diabetes.
Chris has taken his personal journey of living with diabetes and added this to his work with patient groups and healthcare professionals to develop a product that is individual and focusses on improving the development of future complications. Gendius in the last 12 months have won Innovate grant funding for a study in patients with Diabetic Foot Ulcers and in addition SBRI funding for a feasibility study in Gestational Diabetes.
www.gendius.co.uk